Literature DB >> 18945778

Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Hiroyu Hatano1, Eric L Delwart, Philip J Norris, Tzong-Hae Lee, Joan Dunn-Williams, Peter W Hunt, Rebecca Hoh, Susan L Stramer, Jeffrey M Linnen, Joseph M McCune, Jeffrey N Martin, Michael P Busch, Steven G Deeks.   

Abstract

A subset of antiretroviral-untreated, human immunodeficiency virus (HIV)-infected individuals are able to maintain undetectable plasma HIV RNA levels in the absence of antiretroviral therapy. These "elite" controllers are of high interest as they may provide novel insights regarding host mechanisms of virus control. The degree to which these individuals have residual plasma viremia has not been well defined. We performed a longitudinal study of 46 elite controllers, defined as HIV-seropositive, antiretroviral-untreated individuals with plasma HIV RNA levels of <50 to 75 copies/ml. The median duration of HIV diagnosis was 13 years, the median baseline CD4(+) T-cell count was 753 cells/mm(3), and the median duration of follow-up was 16 months. Plasma and cellular HIV RNA levels were measured using the transcription-mediated amplification (TMA) assay (estimated limit of detection of <3.5 copies RNA/ml). A total of 1,117 TMA assays were performed (median of five time points/subject and four replicates/time point). All but one subject had detectable plasma HIV RNA on at least one time point, and 15 (33%) subjects had detectable RNA at all time points. The majority of controllers also had detectable cell-associated RNA and proviral DNA. A mixed-effect linear model showed no strong evidence of change in plasma RNA levels over time. In conclusion, the vast majority (98%) of elite controllers had measurable plasma HIV RNA, often at levels higher than that observed in antiretroviral-treated patients. This confirms the failure to eradicate the virus, even in these unique individuals who are able to reduce plasma viremia to very low levels without antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18945778      PMCID: PMC2612329          DOI: 10.1128/JVI.01763-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group.

Authors:  J B Hubert; M Burgard; E Dussaix; C Tamalet; C Deveau; J Le Chenadec; M L Chaix; E Marchadier; J L Vildé; J F Delfraissy; L Meyer
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

2.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

3.  CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.

Authors:  Matthew J Dolan; Hemant Kulkarni; Jose F Camargo; Weijing He; Alison Smith; Juan-Manuel Anaya; Toshiyuki Miura; Frederick M Hecht; Manju Mamtani; Florencia Pereyra; Vincent Marconi; Andrea Mangano; Luisa Sen; Rosa Bologna; Robert A Clark; Stephanie A Anderson; Judith Delmar; Robert J O'Connell; Andrew Lloyd; Jeffrey Martin; Seema S Ahuja; Brian K Agan; Bruce D Walker; Steven G Deeks; Sunil K Ahuja
Journal:  Nat Immunol       Date:  2007-10-21       Impact factor: 25.606

4.  Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.

Authors:  Maureen P Martin; Ying Qi; Xiaojiang Gao; Eriko Yamada; Jeffrey N Martin; Florencia Pereyra; Sara Colombo; Elizabeth E Brown; W Lesley Shupert; John Phair; James J Goedert; Susan Buchbinder; Gregory D Kirk; Amalio Telenti; Mark Connors; Stephen J O'Brien; Bruce D Walker; Peter Parham; Steven G Deeks; Daniel W McVicar; Mary Carrington
Journal:  Nat Genet       Date:  2007-05-13       Impact factor: 38.330

5.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Authors:  Florencia Pereyra; Marylyn M Addo; Daniel E Kaufmann; Yang Liu; Toshiyuki Miura; Almas Rathod; Brett Baker; Alicja Trocha; Rachel Rosenberg; Elizabeth Mackey; Peggy Ueda; Zhigang Lu; Daniel Cohen; Terri Wrin; Christos J Petropoulos; Eric S Rosenberg; Bruce D Walker
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

Review 6.  Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.

Authors:  Steven G Deeks; Bruce D Walker
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

7.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Authors:  Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

8.  HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.

Authors:  Asier Sáez-Cirión; Christine Lacabaratz; Olivier Lambotte; Pierre Versmisse; Alejandra Urrutia; Faroudy Boufassa; Françoise Barré-Sinoussi; Jean-François Delfraissy; Martine Sinet; Gianfranco Pancino; Alain Venet
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-11       Impact factor: 11.205

9.  A whole-genome association study of major determinants for host control of HIV-1.

Authors:  Jacques Fellay; Kevin V Shianna; Dongliang Ge; Sara Colombo; Bruno Ledergerber; Mike Weale; Kunlin Zhang; Curtis Gumbs; Antonella Castagna; Andrea Cossarizza; Alessandro Cozzi-Lepri; Andrea De Luca; Philippa Easterbrook; Patrick Francioli; Simon Mallal; Javier Martinez-Picado; José M Miro; Niels Obel; Jason P Smith; Josiane Wyniger; Patrick Descombes; Stylianos E Antonarakis; Norman L Letvin; Andrew J McMichael; Barton F Haynes; Amalio Telenti; David B Goldstein
Journal:  Science       Date:  2007-07-19       Impact factor: 47.728

10.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

View more
  119 in total

1.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Comprehensive analysis of unique cases with extraordinary control over HIV replication.

Authors:  Daniel Mendoza; Sarah A Johnson; Bennett A Peterson; Ven Natarajan; Maria Salgado; Robin L Dewar; Peter D Burbelo; Nicole A Doria-Rose; Erin H Graf; Jamieson H Greenwald; Jessica N Hodge; William L Thompson; Nancy A Cogliano; Cheryl L Chairez; Catherine A Rehm; Sara Jones; Claire W Hallahan; Joseph A Kovacs; Irini Sereti; Omar Sued; Sheila A Peel; Robert J O'Connell; Una O'Doherty; Tae-Wook Chun; Mark Connors; Stephen A Migueles
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

3.  HIV controllers with HLA-DRB1*13 and HLA-DQB1*06 alleles have strong, polyfunctional mucosal CD4+ T-cell responses.

Authors:  April L Ferre; Peter W Hunt; Delandy H McConnell; Megan M Morris; Juan C Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

4.  Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.

Authors:  April L Ferre; Donna Lemongello; Peter W Hunt; Megan M Morris; Juan Carlos Garcia; Richard B Pollard; Hal F Yee; Jeffrey N Martin; Steven G Deeks; Barbara L Shacklett
Journal:  J Virol       Date:  2010-07-28       Impact factor: 5.103

5.  Early immune senescence in HIV disease.

Authors:  Seema Desai; Alan Landay
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

6.  Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus.

Authors:  Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 7.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

8.  Determination of HIV Status in African Adults With Discordant HIV Rapid Tests.

Authors:  Jessica M Fogel; Estelle Piwowar-Manning; Kelsey Donohue; Vanessa Cummings; Mark A Marzinke; William Clarke; Autumn Breaud; Agnès Fiamma; Deborah Donnell; Michal Kulich; Jessie K K Mbwambo; Linda Richter; Glenda Gray; Michael Sweat; Thomas J Coates; Susan H Eshleman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-08-01       Impact factor: 3.731

9.  HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients.

Authors:  Alan Landay; Elizabeth T Golub; Seema Desai; Jinbing Zhang; Val Winkelman; Kathryn Anastos; Helen Durkin; Mary Young; Maria C Villacres; Ruth M Greenblatt; Philip J Norris; Michael P Busch
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

10.  Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers.

Authors:  Florencia Pereyra; Janet Lo; Virginia A Triant; Jeffrey Wei; Maria J Buzon; Kathleen V Fitch; Janice Hwang; Jennifer H Campbell; Tricia H Burdo; Kenneth C Williams; Suhny Abbara; Steven K Grinspoon
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.